MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
29.04
-2.93 (-9.16%)
At close: Apr 28, 2026, 4:00 PM EDT
29.30
+0.26 (0.90%)
After-hours: Apr 28, 2026, 5:35 PM EDT
MBX Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for MBX Biosciences stock have an average target of 56, with a low estimate of 18 and a high estimate of 88. The average target predicts an increase of 92.84% from the current stock price of 29.04.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 28, 2026.
Analyst Ratings
The average analyst rating for MBX Biosciences stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Total | 7 | 9 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $66 | Buy | Initiates | $66 | +127.27% | Jan 28, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $77 → $88 | Strong Buy | Maintains | $77 → $88 | +203.03% | Jan 16, 2026 |
| UBS | UBS | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +106.61% | Jan 7, 2026 |
| Stifel | Stifel | Strong Buy Maintains $45 → $50 | Strong Buy | Maintains | $45 → $50 | +72.18% | Dec 19, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Initiates $18 | Strong Sell | Initiates | $18 | -38.02% | Dec 4, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.96
from -2.38
EPS Next Year
-4.12
from -2.96
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.71 | -3.24 | ||||||
| Avg | -2.96 | -4.12 | ||||||
| Low | -3.15 | -6.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.